Feb 24 (Reuters) - Moderna Inc (MRNA.O) will make certain contingent development, commercial and regulatory milestone payments to the U.S. National Institutes of Health (NIH) related to the development of COVID-19 vaccines, the company said in a filing on Friday. Moderna and the U.S. government agency had entered into a license agreement in December related to certain patents concerning the COVID vaccine products, the filing showed. The vaccine maker first disclosed the deal in its fourth-quarter earnings release stating it missed profit estimates hurt by the royalty payment to NIH. Moderna said under the agreement it would pay low single-digit royalties on future net sales and also minimum annual royalties. Our Standards: The Thomson Reuters Trust Principles.